Courbon, Guillaume
Francis, Connor
Gerber, Claire
Neuburg, Samantha
Wang, Xueyan
Lynch, Emily
Isakova, Tamara
Babitt, Jodie L.
Wolf, Myles
Martin, Aline
David, Valentin http://orcid.org/0000-0001-9527-2364
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Institute of Diabetes and Digestive and Kidney Diseases (R01DK102815, R01DK114158, R01DK101730, R01DK102815, R01DK114158, R01DK101730)
U.S. Department of Health & Human Services | NIH | National Institute of Diabetes and Digestive and Kidney Diseases
U.S. Department of Health & Human Services | NIH | National Institute of Diabetes and Digestive and Kidney Diseases
U.S. Department of Health & Human Services | NIH | National Institute of Diabetes and Digestive and Kidney Diseases
U.S. Department of Health & Human Services | NIH | National Institute of Diabetes and Digestive and Kidney Diseases
U.S. Department of Health & Human Services | NIH | National Institute of Diabetes and Digestive and Kidney Diseases
Article History
Received: 10 September 2020
Revised: 23 March 2021
Accepted: 20 April 2021
First Online: 2 August 2021
Competing interests
: V.D. receives research funding from Akebia and has received research funding from Vifor Pharma and consulting honoraria from Keryx Biopharmaceuticals, Vifor Pharma, Luitpold, and Amgen outside of submitted work. M.W. has received personal fees from Akebia, Amag, Amgen, Ardelyx, Diasorin, Keryx, Lutipold, and Sanofi, and grants from the Shire, outside the submitted work. T.I. received personal fees from Kirin and Guidepoint Global, outside the submitted work. J.L.B. has an ownership interest in Ferrumax Pharmaceuticals and has received consulting fees from Keryx Biopharmaceuticals and Disc Medicine outside of submitted work. All other authors have nothing to disclose.